{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:16Z","timestamp":1787067616090,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T00:00:00Z","timestamp":1710633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jiph.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:12:53Z","timestamp":1710821573000},"page":"843-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Ji-young","family":"Son","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e","family":"Porsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooyoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2024.03.021_bib1","unstructured":"Centers for Disease Control and Prevention About antibioitic resistance, \u3008https:\/\/www.cdc.gov\/drugresistance\/about.html\u3009 [accessed 22 September 2023]."},{"issue":"3","key":"10.1016\/j.jiph.2024.03.021_bib2","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2666-5247(22)00355-X","article-title":"Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Langford","year":"2023","journal-title":"Lancet Microbe"},{"issue":"11","key":"10.1016\/j.jiph.2024.03.021_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/tropicalmed7110365","article-title":"Association of multidrug resistance bacteria and clinical outcomes of adult patients with sepsis in the intensive care unit","volume":"7","author":"Al-Sunaidar","year":"2022","journal-title":"Trop Med Infect Dis"},{"issue":"8","key":"10.1016\/j.jiph.2024.03.021_bib4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/antibiotics10080942","article-title":"Alves L.,et al. Bacterial nosocomial infections: multidrug resistance as a trigger for the development of novel antimicrobials","volume":"10","author":"Sousa","year":"2021","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.jiph.2024.03.021_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.jiph.2024.03.021_bib6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/microorganisms11040899","article-title":"The challenge of bacteremia treatment due to non-fermenting gram-negative bacteria","volume":"11","author":"Sadyrbaeva-Dolgova","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib7","first-page":"10","volume":"39","author":"Tsuji","year":"2019","journal-title":"Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.jiph.2024.03.021_bib8","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/jac\/dkac145","article-title":"Leibovici-Weissman Y.,et al. Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis","volume":"77","author":"Margalit","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2024.03.021_bib9","article-title":"Mulrow C.D., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2024.03.021_bib10","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.jiph.2024.03.021_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jiph.2024.03.021_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.021_bib14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00228-013-1493-9","article-title":"Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection","volume":"69","author":"Karnik","year":"2013","journal-title":"Eur J Clin Pharm"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.021_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01957-18","article-title":"Multicenter population pharmacokinetic Study of colistimethate sodium and colistin dosed as in normal renal function in patients on continuous renal replacement therapy","volume":"63","author":"Leuppi-Taegtmeyer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2024.03.021_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijid.2020.08.010","article-title":"Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: a prospective observational study","volume":"100","author":"Moni","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2024.03.021_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/molecules24030530","article-title":"Colistin use in patients with chronic kidney disease: are we underdosing patients?","volume":"24","author":"Sorli","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jiph.2024.03.021_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","article-title":"Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical","volume":"79","author":"Sorli","year":"2019","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.00985-12","article-title":"Karaiskos I.,et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration","volume":"57","author":"Karvanen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jiph.2024.03.021_bib20","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Jansson B.,et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jiph.2024.03.021_bib21","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Tsangaris I.,et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jiph.2024.03.021_bib22","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.00345-09","article-title":"Alamanos I.,et al. Penetration of colistin into cerebrospinal fluid","volume":"53","author":"Markantonis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jiph.2024.03.021_bib23","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dks257","article-title":"Boutzouka E.,et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study","volume":"67","author":"Markou","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clinthera.2008.01.015","article-title":"Karatzas S.,et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study","volume":"30","author":"Markou","year":"2008","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.jiph.2024.03.021_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4103\/ijmr.IJMR_1464_16","article-title":"Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: a pilot study","volume":"147","author":"Gautam","year":"2018","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.jiph.2024.03.021_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2016.06.008","article-title":"Athanassa Z., et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"48","author":"Karaiskos","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jiph.2024.03.021_bib27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"A lotti G., Langer M., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.021_bib28","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiph.2024.03.021_bib29","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Galani L., et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiph.2024.03.021_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.cmi.2020.03.016","article-title":"Daitch V., et al. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria","volume":"26","author":"Kristoffersson","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jiph.2024.03.021_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/pharmacy10040096","article-title":"Drug utilization and potential drug-drug interactions within an intensive care unit at a university tertiary care hospital in Egypt","volume":"10","author":"Obeid","year":"2022","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"10.1016\/j.jiph.2024.03.021_bib32","doi-asserted-by":"crossref","first-page":"R212","DOI":"10.1186\/cc13026","article-title":"Epidemiology of critically ill patients in intensive care units: a population-based observational study","volume":"17","author":"Garland","year":"2013","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bcpt.13482","article-title":"Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome","volume":"128","author":"Ram","year":"2021","journal-title":"Basic Clin Pharm Toxicol"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12941-019-0339-4","article-title":"Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients","volume":"18","author":"Zafer","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.021_bib35","doi-asserted-by":"crossref","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2052-0492-2-31","article-title":"Estimation of renal function in the intensive care unit: the covert concepts brought to light","volume":"2","author":"Sunder","year":"2014","journal-title":"J Intensive Care"},{"issue":"5","key":"10.1016\/j.jiph.2024.03.021_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijantimicag.2009.06.028","article-title":"Clinical characteristics and risk factors of colistin-induced nephrotoxicity","volume":"34","author":"Kim","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.021_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/pharmaceutics14010031","article-title":"Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients","volume":"14","author":"Katip","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.jiph.2024.03.021_bib39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/antibiotics9100647","article-title":"A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: A propensity score-matched analysis","volume":"9","author":"Katip","year":"2020","journal-title":"Antibiot (Basel)"},{"issue":"5","key":"10.1016\/j.jiph.2024.03.021_bib40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2011.07.004","article-title":"Dosing of colistin-back to basic PK\/PD","volume":"11","author":"Bergen","year":"2011","journal-title":"Curr Opin Pharm"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T08:14:17Z","timestamp":1714292057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1876034124000911"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.03.021","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}